Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Real-time Euronext Paris 10:51:10 2024-03-28 am EDT 5-day change 1st Jan Change
91.36 EUR -0.44% Intraday chart for Sanofi +4.16% +1.78%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
SANOFI : Barclays reiterates its Buy rating ZD
Smith & Nephew CFO designate John Rogers to start next week AN
SK Bioscience Signs Deal with Sanofi for Five Vaccine Types MT
Dr. Reddy's Laboratories Signs Deal to Distribute Sanofi's Vaccine Brands MT
Moody's Raises Outlook on Sanofi to Positive on Expected Earnings Growth MT
Novo Nordisk, Eli Lilly, Sanofi Control More Than 90% of Global Insulin Market, JAMA Study Shows MT
AstraZeneca's RSV Disease Drug, Breast Cancer Combination Therapy Receive Approval in Japan MT
FTSE 100 underperforms ahead of US PCE data AN
AstraZeneca treatments become "first and only" to be approved in Japan AN
FTSE 100 slips as unease lingers before US data AN
AstraZeneca: Beyfortus approved in Japan CF
Diploma makes buy; Astra wins Japan drug approvals AN
AstraZeneca, Sanofi's RSV Prevention Drug Wins Japanese Approval MT
Cipla to Distribute Sanofi's CNS Product Line in India MT
Dyne Therapeutics President, CEO Joshua Brumm Resigns, John Cox Named Successor; Shares Drop 7% Pre-Bell MT
Adocia: announces fund-raising CF
Skin care company Galderma's shares open higher on stock market debut RE
Eli Lilly: recycling solution for insulin pens CF
Sanofi: French solution for recycling insulin pens CF
CAC40: Paris and E-Stoxx50 close at record highs CF
CAC40: in record territory, oil at year's high CF
CAC40: new rebound after BoJ and ZEW indexes CF
CAC 40: no major upheaval after BoJ meeting CF
AstraZeneca follows rival Boehringer in capping out-of-pocket costs for inhalers RE
Euroapi: production suspended in Brindisi CF
Chart Sanofi
More charts
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
91.76 EUR
Average target price
107.6 EUR
Spread / Average Target
+17.29%
Consensus
  1. Stock
  2. Equities
  3. Stock Sanofi - Euronext Paris
  4. News Sanofi
  5. Sanofi Says Nirsevimab Showed Nearly 80% Efficacy Against Respiratory Syncytial Virus